Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Combivir opvejer risiciene ved antiretroviral kombinationsbehandling af hiv- infektion.
The Committee for Medicinal Products for Human Use (CHMP) decided that Combivir’ s benefits are greater than its risks in antiretroviral combination therapy for the treatment of HIV infection.